Search
Brifentanil
go.drugbank.com/drugs/DB09172ExperimentalIllicitBrifentanil (also known as A-3331) is an analog of fentanyl, a potent opioid. This drug is classified as an opioid analgesic and was developed in the early 1990s.
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigationalRelugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. … [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous
Categories: Gonadotropin Releasing Hormone Receptor AntagonistsBrolucizumab
go.drugbank.com/drugs/DB14864ApprovedInvestigationalBrolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
RR001
go.drugbank.com/drugs/DB17369Investigational(AD-PC sTRAIL). … RR001 is an investigational gene therapy consisting of autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
Inetetamab
go.drugbank.com/drugs/DB17457InvestigationalInetetamab is a trastuzumab analog. It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.
Clevidipine
go.drugbank.com/drugs/DB04920ApprovedInvestigationalClevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
AC3056
go.drugbank.com/drugs/DB05230ExperimentalAC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. … It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.
Deudextromethorphan
go.drugbank.com/drugs/DB19054InvestigationalDeudextromethorphan is under investigation in clinical trial NCT02153502 (Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an
Pentaerythritol tetranitrate
go.drugbank.com/drugs/DB06154ApprovedWithdrawnWhen mixed with a plasticizer, this chemical forms a plastic explosive. It is recognized by the FDA to be a coronary vasodilator in the treatment of heart conditions such as angina [L2395]. … It is then filtered out, washed, dried, and recrystallized to produce a colorless crystalline material that is stored and shipped as a mixture with water and alcohol [L2394].